Cargando…

Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare

Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide. Refractory patients are exposed to many complications, notably accelerated atherosclerosis. We report a case report of 71-year-old man followed for polyarteritis nodosa refra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Emmanuel, Cressend, Thomas, Duffau, Pierre, Grenouillet-Delacre, Marieke, Rouanet-Larivière, Marie, Vital, Anne, Longy-Boursier, Maïté, Mercié, Patrick
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838226/
https://www.ncbi.nlm.nih.gov/pubmed/20300599
http://dx.doi.org/10.1155/2009/738293
_version_ 1782178867465682944
author Ribeiro, Emmanuel
Cressend, Thomas
Duffau, Pierre
Grenouillet-Delacre, Marieke
Rouanet-Larivière, Marie
Vital, Anne
Longy-Boursier, Maïté
Mercié, Patrick
author_facet Ribeiro, Emmanuel
Cressend, Thomas
Duffau, Pierre
Grenouillet-Delacre, Marieke
Rouanet-Larivière, Marie
Vital, Anne
Longy-Boursier, Maïté
Mercié, Patrick
author_sort Ribeiro, Emmanuel
collection PubMed
description Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide. Refractory patients are exposed to many complications, notably accelerated atherosclerosis. We report a case report of 71-year-old man followed for polyarteritis nodosa refractory to glucocorticoids and cyclosphosphamide. Systemic vasculitis relapses are followed to accelerated atherosclerosis: severe ischemic lesions led to amputation of lower limbs. Remission of refractory PAN is obtained with rituximab. Disappearance of biological inflammatory is allowed to regression of ischemic lesions in upper limbs. In this situation, we recommend a systematic vascular work-up for patients suffered from refractory vasculitis. On the other hand, therapeutic trials are needed to determine the real efficacy and place of rituximab in the treatment of polyarteritis nodosa.
format Text
id pubmed-2838226
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28382262010-03-18 Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare Ribeiro, Emmanuel Cressend, Thomas Duffau, Pierre Grenouillet-Delacre, Marieke Rouanet-Larivière, Marie Vital, Anne Longy-Boursier, Maïté Mercié, Patrick Case Rep Med Case Report Polyarteritis nodosa (PAN) is a systemic vasculitis whose severe forms are treated with glucocorticoids and cyclophosphamide. Refractory patients are exposed to many complications, notably accelerated atherosclerosis. We report a case report of 71-year-old man followed for polyarteritis nodosa refractory to glucocorticoids and cyclosphosphamide. Systemic vasculitis relapses are followed to accelerated atherosclerosis: severe ischemic lesions led to amputation of lower limbs. Remission of refractory PAN is obtained with rituximab. Disappearance of biological inflammatory is allowed to regression of ischemic lesions in upper limbs. In this situation, we recommend a systematic vascular work-up for patients suffered from refractory vasculitis. On the other hand, therapeutic trials are needed to determine the real efficacy and place of rituximab in the treatment of polyarteritis nodosa. Hindawi Publishing Corporation 2009 2010-03-14 /pmc/articles/PMC2838226/ /pubmed/20300599 http://dx.doi.org/10.1155/2009/738293 Text en Copyright © 2009 Emmanuel Ribeiro et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ribeiro, Emmanuel
Cressend, Thomas
Duffau, Pierre
Grenouillet-Delacre, Marieke
Rouanet-Larivière, Marie
Vital, Anne
Longy-Boursier, Maïté
Mercié, Patrick
Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
title Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
title_full Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
title_fullStr Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
title_full_unstemmed Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
title_short Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
title_sort rituximab efficacy during a refractory polyarteritis nodosa flare
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838226/
https://www.ncbi.nlm.nih.gov/pubmed/20300599
http://dx.doi.org/10.1155/2009/738293
work_keys_str_mv AT ribeiroemmanuel rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT cressendthomas rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT duffaupierre rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT grenouilletdelacremarieke rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT rouanetlarivieremarie rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT vitalanne rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT longyboursiermaite rituximabefficacyduringarefractorypolyarteritisnodosaflare
AT merciepatrick rituximabefficacyduringarefractorypolyarteritisnodosaflare